[2-ω-phenylalkyl)phenoxy]alkylamines: Synthesis and dual dopamine2 (D2) and 5-hydroxytryptamine2 (5-HT2) receptor antagonistic activities

Chemical and Pharmaceutical Bulletin

Volumn 46, Issue 4, 1998, Pages 639-646

  Tanaka, Naoki ^a   Goto, Riki ^a   Ito, Rie ^a   Hayakawa, Miho ^a   Ogawa, Taketoshi ^a   Fujimoto, Koichi ^a  

^a DAIICHI SANKYO CO   (Japan)

Author keywords

5 hydroxytryptamine2 (5 HT2); Antagonistic activity; Dopamine2 (D2); Dual antagonist; 2 (4 phenylbutyl) phenoxy alkylamine

Indexed keywords

ALIPHATIC AMINE; CHLORPROMAZINE; DOPAMINE 2 RECEPTOR; DOPAMINE 2 RECEPTOR BLOCKING AGENT; FLUPHENAZINE; HALOPERIDOL; PEROSPIRONE; RISPERIDONE; SARPOGRELATE; SEROTONIN 2 ANTAGONIST; SEROTONIN 2 RECEPTOR; UNCLASSIFIED DRUG; [2 (4 PHENYLBUTYL)PHENOXY]METHYLPIPERIDINE DERIVATIVE;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; BRAIN CORTEX; CONTROLLED STUDY; DOPAMINE RECEPTOR BLOCKING; DRUG POTENCY; DRUG RECEPTOR BINDING; DRUG STRUCTURE; DRUG SYNTHESIS; MALE; MOUSE; NONHUMAN; RAT; SMOOTH MUSCLE CONTRACTILITY; STRUCTURE ACTIVITY RELATION; VASCULAR SMOOTH MUSCLE;

EID: 0031976707     PISSN: 00092363     EISSN: None     Source Type: Journal    
DOI: 10.1248/cpb.46.639     Document Type: Article

References (18)

1. a) Lader M., J. Int. Med. Res., 17, 1-16 (1989);
2. b) Hollister L. E., Drug Dev. Res., 9, 9-21 (1986).
3. Remington G., Can. J. Psychiatry., 34, 211-220 (1989).
4. a) Bersani G., Grispini A., Marini S., Pasini A., Valducci M., Ciani N., Curr. Ther. Res., 40, 492-500 (1986);
5. b) Reyntjens A., Gelders Y. G., Hoppenbrouwers M.-L. J. A., Vanden Bussche G., Drug Dev. Res., 8, 205-211 (1986);
6. Meltzer H. Y., Nash J. F., Pharmacol. Rev., 43, 587-604 (1991).
7. Janssen P. A. J., Niemegeers C. J. E., Awouters F., Schellekens K. H. L., Megens A. A. H. P., Meert T. F., J. Pharmacol. Exp. Ther., 244, 685-693 (1988).
8. Hirose A., Kalo T., Ohno Y., Shimizu H., Tanaka H., Nakamura M., Katsube J., Jpn. J. Pharmacol., 53, 321-329 (1990).
9. Kikumoto R., Hara H., Ninomiya K., Osakabe M., Sugano M., Fukami H., Tamao Y., J. Med. Chem., 33, 1818-1823 (1990).
10. Mitsunobu O., Synthesis, 1981, 1-28.
11. Leo A., Weininger D., "CLOGP3 Reference Manual, Daylight Software 4.34," Daylight Chemical Information Systems, Inc., Irvine.
12. Fujimoto K., Tanaka N., Asai F., Ito T., Koike H., Eur. Pat. EP600717 (1994) [Chem. Abstr., 123, 169510k (1995)].
13. Fujimoto K., Tanaka N., Asai F., Ito T., Koike H., Eur. Pat. EP600717 (1994) [Chem. Abstr., 123, 169510k (1995)].
14. Leysen J. E., Niemegeers C. J. E., Van Nueten J. M., Laduron P. M., Mol. Pharmacology., 21, 301-314 (1982).
15. Van Nueten J. M., Janssen P. A. J., Van Beek J., Xhonneux R., Verbeuren T. J., Vanhoutte P. M., J. Pharmacol. Exp. Ther., 218, 217-230 (1981).
16. Köhler C., Hall H., Ögren S., Gawell L., Biochem. Pharmacol., 34, 2251-2259 (1985).
17. Protais P., Costentin J., Schwartz J. C., Psychopharmacology., 50, 1-6 (1976).
18. Neuroscience Research Laboratories, Sankyo Co., Ltd.